Cronos Group Inc.

NASDAQ:CRON

Drug Manufacturers - Specialty & Generic

Healthcare
$3.17 -0.56%

-$0.02 today

Market cap
$1.16B
Beta
1.25
P/E (TTM)
-488.3
EPS (TTM)
-$0.01
52W Low $1.84High $3.43

Volume 1.13M

Average 1.51M

CRON EBITDA Margin

EBITDA as a percentage of revenue.

Cronos Group Inc.NASDAQ: CRON

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 5.0%

EBITDA Margin was 5.0% in Q1 FY2026, up 7.1 pp from a year earlier. On a trailing-twelve-month basis it was -5.9%, up 25.2 pp year over year. Over 3 fiscal years it widened by 103.0 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 41.3% for the fiscal year ending Dec 2026, up from -2.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
5.0%+53.8 pp QoQ
Last fiscal yearDec 2025
-2.3%+40.4 pp YoY
LTMMar 2026
-5.9%+25.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+7.1 pp+17.3 pp+10.1 pp
1 year+40.4 pp+43.5 pp+3.1 pp
3 years+103.0 pp+38.5 pp-64.5 pp
5 years+36.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-2.3%
Year-over-year change
+40.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CRON compares with its peers on the latest reported figures

  • CRON's LTM Mar 2026 EBITDA Margin of -5.9% is the 7th highest of the 10 companies compared; the peer median is 26.6%.
  • Its year-over-year change of +25.2 pp is the 4th highest of 9, against a peer median of +11.6 pp.
  • Over three fiscal years its change of +103.0 pp compares with a peer median of +0.2 pp.
CRON Competitors Peer median
EBITDA Margin for CRON and competitors
Company Period LTM level YoY 3-year change
COLLCollegium Pharmaceutical, Inc.LTM Mar 202676.6% +26.5 pp+14.0 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202646.0% +315.4 pp+147.4 pp
IRMDIRadimed CorporationLTM Mar 202637.4% +3.1 pp+5.1 pp
EMBCEmbecta Corp.LTM Mar 202630.9% +11.2 pp-2.3 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202626.6% -9.0 pp+0.2 pp
PCRXPacira BioSciences, Inc.LTM Mar 202616.1% +12.1 pp-4.2 pp
CRONCronos Group Inc.LTM Mar 2026-5.9% +25.2 pp+103.0 pp
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026-44.4% +288.1 pp—
XNCRXencor, Inc.LTM Jun 2026-117.7% -51.9 pp-9.6 pp
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-590.7% ——
BBOTBridgeBio Oncology Therapeutics Inc.FY2025— ——
Peer median (excluding CRON) 26.6%+11.6 pp+0.2 pp

Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue64.56M86.75M87.24M117.62M149.15M
Cost of Revenue82.15M71.31M75.33M92.42M87.45M
Gross Profit(17.59M)15.44M11.91M25.2M61.7M
Gross Margin-27.3%17.8%13.7%21.4%41.4%
Research & Development21.84M13.13M5.84M4.23M4.45M
Selling, General & Admin121.68M100.73M80.93M76.82M63.76M
Operating Expenses274.38M126.86M96.71M101.73M79.54M
Depreciation & Amortization15.4M13.12M8.11M9.34M14.48M
EBITDA(150.13M)(91.27M)(71.8M)(50.21M)(3.36M)
EBITDA Margin-232.5%-105.2%-82.3%-42.7%-2.3%
Operating Income(291.97M)(111.43M)(84.8M)(76.53M)(17.84M)
Operating Margin-452.2%-128.4%-97.2%-65.1%-12.0%
Interest Income9.07M22.51M51.24M52.02M40.66M
Interest Expense27K13K000
Other Income / Expenses163.46M(9.58M)11.13M113.12M419.21K
Income Before Tax(128.51M)(121M)(73.67M)36.59M(17.42M)
Pre-Tax Margin-199.1%-139.5%-84.4%31.1%-11.7%
Income Tax Expense(431K)34.18M(3.23M)(3.44M)(14.44M)
Net Income(396.11M)(168.73M)(73.96M)41.08M(9.61M)
Net Margin-613.5%-194.5%-84.8%34.9%-6.4%
EPS (Basic)(1.07)(0.45)(0.19)0.11(0.03)
EPS (Diluted)(1.07)(0.45)(0.19)0.11(0.03)
Weighted Avg Shares370.39M376.96M403.4M382.06M385.31M
Weighted Avg Shares (Diluted)370.39M376.96M380.97M385.56M385.31M

Cronos Group Inc.

NASDAQ:CRON

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.